Navigation Links
Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
Date:8/28/2008

TITUSVILLE, N.J., Aug. 28 /PRNewswire/ -- Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for RAZADYNE(R) (galantamine hydrobromide) is invalid.

The decision allows FDA-approved generic versions of immediate-release galantamine hydrobromide to enter the U.S. marketplace "at risk" pending an appeal. A favorable ruling would have provided patent protection for RAZADYNE(R) IR until the patent expires on December 14, 2008.

"We are disappointed by the court's decision and will appeal this ruling," said Janet Vergis, President of Janssen and Ortho-McNeil Neurologics. "We believe the patent protecting RAZADYNE(R) is valid and would be infringed by the introduction of a generic galantamine hydrobromide product."

Barr Laboratories and AlphaPharm Pty Ltd. filed Abbreviated New Drug Applications ("ANDAs") to market galantamine hydrobromide before the expiration of the patent, claiming the patent was invalid. Janssen, Janssen Pharmaceutica N.V., and patent owner Synaptech Inc. filed a patent infringement complaint against Barr and AlphaPharm in June 2005. Other lawsuits against generic companies seeking to market galantamine hydrobromide before the expiration of the patent are bound by the outcome of this case.

RAZADYNE and RAZADYNE ER are marketed by Ortho-McNeil Neurologics in the United States, and are indicated in the treatment of mild to moderate dementia of the Alzheimer's type.

Important Safety Information

In clinical trials, the most common side effects are nausea, vomiting, diarrhea, loss of appetite and weight loss. Typically, these side effects are mild and temporary. RAZADYNE(R) and RAZADYNE(R) ER may not be for everyone. Some people experience a slowed heart rate, which may lead to fainting. Serious stomach problems can occur in people taking medications such as nonsteroid
'/>"/>

SOURCE Ortho-McNeil Neurologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
2. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
3. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
4. Insmed to Appeal Delisting Notification From Nasdaq
5. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
6. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
7. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
11. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global N-acetylcysteine Industry Report 2014 2
... Medivation, Inc. (Nasdaq: MDVN ) today announced several ... MDV3100 and Dimebon. MDV3100 , 2009 American Urological ... , Podium presentation ... (POD17. Prostate Cancer: Advanced , , ...
... China Sky One,Medical, Inc. ("China Sky One Medical" or ... integrated pharmaceutical company producing over-the-counter,drugs in the People,s Republic ... the State Food and Drug Administration (SFDA) in China,for ... pain relief. , Geranium ointment ...
... - Fourth Quarter 2008 Revenue Increased 28.6% to $14.1 Million, ... EPS of $.03, - 2008 Revenues Increased 23.5% to $59.1 ... Basis Points to 20.1%, - 2008 Net Income Increased 13.7% ... - 2008 Cash Flow from Operations was $5.9 million, , ...
Cached Biology Technology:Medivation Announces Upcoming Scientific Presentations at Medical Conferences 2Medivation Announces Upcoming Scientific Presentations at Medical Conferences 3China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 2China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11
(Date:9/18/2014)... Sticklebacks, the roaches of the fish world, are the ... control body shape. They,ve moved from the ocean into ... the world, each time changing their skeleton to adapt ... and freshwater populations of sticklebacks now have turned up ... evidence that a simple change in that gene,s regulation ...
(Date:9/18/2014)... swim up to 400 kilometres in search of a home, ... , Clownfish spend their entire adult lives under the protection ... the open ocean, says study co-author, Dr Hugo Harrison from ... CoE) at James Cook University. , "In the past we ... a rare glimpse into how far they can swim, crossing ...
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... of the standard dose of a commonly used meningitis ... dose. This new finding should allow scarce vaccine resources ... In a study initiated by the Norwegian Institute ... of Doctors Without Borders/Mdecins Sans Frontires), and Mbarara University ...
... has identified the precise location of the bone marrow stem ... Online Publication of Nature . The Linheng Li ... develop a new technology ex vivo Imaging of Stem ... stem cells. This technology enabled the team to track the ...
... Va. -- The Virginia Tech Wake Forest University,s School ... received the Army Modeling and Simulation Award for 2008. ... the Army and Director of the Army presented the award ... morbidity and mortality associated with facial injury. The ...
Cached Biology News:Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2New dummy design and development wins US Department of Defense award 2
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Biology Products: